Skip to main content

Table 2 Main results of the base-case cost-effectiveness analysis. Abbreviations: CNY, Chinese yuan

From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

 

IDegLira

(mean [SD])

Liraglutide

(mean [SD])

IDegLira

(mean [SD])

degludec

(mean [SD])

Life expectancy (years)

14.007

(0.114)

13.975

(0.111)

13.952

(0.109)

13.909

(0.115)

Quality-Adjusted Life expectancy (years)

12.081

(0.098)

12.007

(0.096)

12.031

(0.093)

11.963

(0.100)

Direct costs(CNY)

507788.938

(6972.7)

535734.375

(7272.03)

506767.563

(6,950.79)

507,963.13

(6,726.01)